These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21976354)

  • 1. Evaluations of new drugs after they reach the market.
    Jirillo A; Trojniak MP
    Health Aff (Millwood); 2011 Oct; 30(10):2028. PubMed ID: 21976354
    [No Abstract]   [Full Text] [Related]  

  • 2. Withdrawing unsafe drugs from the market.
    Dhruva SS; Redberg RF
    Health Aff (Millwood); 2011 Nov; 30(11):2218. PubMed ID: 22068420
    [No Abstract]   [Full Text] [Related]  

  • 3. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical approval success rates for investigational cancer drugs.
    DiMasi JA; Reichert JM; Feldman L; Malins A
    Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials of unapproved medicines in Australia.
    Rankin J; Mason J; Kottege N; Andersson NY
    Med J Aust; 2006 Sep; 185(6):342-3. PubMed ID: 16999682
    [No Abstract]   [Full Text] [Related]  

  • 7. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 8. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 10. [Off-label use in oncology. The Italian choice].
    Felicetti V; Gremigni U; Cifaldi L
    Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 14. Market watch: Upcoming market catalysts in Q1 2014.
    Stopke E
    Nat Rev Drug Discov; 2014 Jan; 13(1):11. PubMed ID: 24378790
    [No Abstract]   [Full Text] [Related]  

  • 15. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 16. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 17. Market watch: Upcoming market catalysts in Q1 2017.
    Fulton Z
    Nat Rev Drug Discov; 2016 Dec; 16(1):11. PubMed ID: 28031567
    [No Abstract]   [Full Text] [Related]  

  • 18. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 19. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.